

TO THE RELEVANT COMPETENT AUTHORITIES

IBOGA

Gabon's Last Window of Economic Sovereignty

Global Science • Patents • Industry • China • Sovereignty • Immediate Action

The world is accelerating. Gabon can become a leader—or let its heritage become someone else's industry.

By Yann GUIGNON

Founder and President of Blessings Of The Forest – Gabon



The real issue: a strategic rent is being created without Gabon

≈ \$1 billion

capital already mobilized around ibogaine companies — an industry projected to be 5× larger by 2030

\$200 million

U.S. public funds committed to ibogaine as of July 2026

\$500 million

Projected U.S. public funding over 4–5 years

133

iboga/ibogaine patent documents in the global database as of March 2026 — 0 Gabonese patents identified

Political analysis: This is no longer an “exotic” or purely medical topic. It is a competition over assets, intellectual property, standards, clinical data, and sovereignty.

What Gabon fails to capture today will become foreign revenue tomorrow.

Three useful steps for deciding now

PRIDE

Gabon is home to the cultural origins, biodiversity, and traditional knowledge that have given iboga its significance around the world.

SHAME

Foreign universities, foundations, and governments are already transforming this heritage into patents, protocols, companies, and clinics.

REDRESS

Chemistry, fermentation, and industrial production lines may soon bypass the plant—but not Gabon's rights, if they are enforced.

Objective of the presentation: to transform a heritage alert into a government decision.

What the United States is already doing... and what Gabon must do now

UNITED STATES

- Public funds: \$200 million already committed
- Projection: \$500 million over 4–5 years
- Trump / HHS / ARPA-H / NIH / FDA mobilized
- Universities: Stanford, Harvard, Columbia, UC Davis
- Biotech companies: Soneira, Gilgamesh, Delix, DemeRx, ATAI
- Rationale: clinical trials + IP + future revenue

GABON

- No National Conference has been organized yet
- No fully operational dedicated national authority
- No structured and funded patent monitoring system
- No integrated clinical/R&D/industrial ecosystem
- BUT: Decree 2026 + LSP/GMP facility + expertise + legitimacy
- Decision: **MOVE FROM PROTECTION TO A SOVEREIGN INDUSTRY**

Gabon's administrative time is no longer in sync with the rest of the world.

The key figure to emphasize: this isn't just a niche market—it's a global market

Total addressable market for potential uses of ibogaine

\$766 billion

Potential U.S. market

\$6.6 Trillion

Potential global market


\$19.8 billion

Illustrative scenario: 3% of the global market × 10% captured by Gabon

≈ 11,400 billion CFA francs

(projected and strategic order of magnitude for immediate policy decision-making)

The potential scale exceeds the budgets the government is already allocating



Gabon knows how to raise billions for infrastructure. It must now raise a few billion to attract a global industry before it becomes established elsewhere.

American scientific talent is already mobilized

Stanford from Catalyst4	→	Soneira	ibogaine + magnesium / TBI-PTSD	\$25 million, including \$15 million
Harvard	→	NIH / NIDA	addictions / opioids	≈ \$11 million in public funding
Columbia	→	Gilgamesh	oxa-noribogaine / analogs	≈ \$200 million raised / major deals
While top U.S. universities are transforming ibogaine into industrial assets, Gabon must create its own scientific and economic framework.				
UC Davis	→	Delix	tabernanthalog / plant-independent synthesis	> \$100 million raised

Sources: Barsuglia 2026; BOTF/Barsuglia report, April 2026.

Foreign intellectual property is advancing faster than the Gabonese government

133

Iboga/ibogaine patent documents in the global database, March 2026

99

Documents in the United States

94

Documents associated with DemeRx in the database

0

Gabonese Strategic Portfolio identified

What is Patented

- Chemical Analogs
- formulations / routes of administration
- safety and monitoring protocols
- Treatment Methods: Addiction, PTSD, TBI, Depression

Gabonese response

- ongoing patent monitoring
- National Register of Intellectual Property and Prior Art
- third-party observations / oppositions / litigation
- licenses, royalties, Nagoya sharing

Policy: No foreign patent related to iboga should remain without analysis and a response strategy.

China does not control iboga. But it could enter the market very quickly.

What has been confirmed

- Expert analysis on iboga-type alkaloids
- CAS-affiliated co-author on ibogaine biosynthesis
- Foreign patents seeking protection in China
- Industrial capacity for APIs and fine chemicals

What has not been proven

- No official Chinese program identified
- No government oversight of Gabonese iboga
- No major clinical trials visible
- No established major Chinese portfolio

The Real Risk

- Industrial bypass of Gabon
- Chemical synthesis / precursors
- Fermentation / biotechnology
- Industrial contracts or rapid African partnerships

Message: The danger today is not evidence of a “Chinese conspiracy”; the danger is the absence of a Gabonese strategy tomorrow.

The export ban is no longer enough

Voacanga africana

Semi-synthetic ibogaine derived from voacangine, often produced outside Gabonese control

Total synthesis

Production from pyridine: supply chain without African plants

Fermentation

Yeast biosynthesis / Bioreactors in the medium term

What no one can bypass: traditional knowledge, cultural legitimacy, the national decree, the Nagoya Protocol, WIPO, and a Gabonese industrial platform, if it is activated.

Decree 2026 finally provides a weapon: it must be used



National Strategic Heritage

iboga, alkaloid derivatives, ibogaine

Interministerial Commission

Sovereign, technical, and scientific decision

Regulated patents

monitoring, opposition, licensing, litigation

Prior Authorization

Any activity under state control

Equitable sharing

Government + resource-holding communities

Sovereign wealth fund

supply chain, research, conservation, culture

A decree without a budget becomes a symbol. A decree put into effect becomes a sovereign income stream.

Gabon already has an industrial base: the pharmaceutical sector

MINISTÈRE DE LA SANTÉ ET DES
AFFAIRES SOCIALES
CABINET DU MINISTRE
AGENCE DU MÉDICAMENT
SERVICE DES AFFAIRES
RÉGLEMENTAIRES ET DE LA
PHARMACOPHIE

Certificat N° 001/AM/BPF/22
CERTIFICAT DE CONFORMITÉ AUX BONNES PRATIQUES DE FABRICATION : Fabricant et/ou Exploitant
Le Directeur de l'Agence du Médicament,
Sur la base de l'inspection qui s'est déroulée du 19 au 20 Mai 2022

Certifie que :
Nom de la société et l'adresse du siège social : **La Santé Pharmaceutique SA**
Nom et adresse du site de production: **E-2, GSEZ Nkok, BP 901, Libreville Gabon**
Arrêté d'ouverture / fiche technique N°00222/MSPSSN/SG

Activité
Fabrication de la substance active ☐
Nom de la substance active :
ou
Fabrication (partielle) du produit fini ☒
Étape de fabrication (p. ex. mélange, mélange, fabrication des comprimés, etc. ou « toutes »)
et
Libération de lot du produit fini ☒
(packaging, contrôle de qualité, etc.)

Conformité aux BPF
La fabrication décrite dans l'annexe I est conforme aux prescriptions suivantes (selon ce qui convient) :
☒ Guide des bonnes pratiques de fabrication pour les médicaments à usage humain et les médicaments à usage vétérinaire :
Guide OMS des normes relatives aux bonnes pratiques de fabrication BPF WHO_VSQ_97.01
☐ Autres normes (BPF agro-alimentaires, BPF pour les cosmétiques) :
Cette déclaration repose sur une inspection/audit du fabricant et les informations complémentaires fournies
(exception possible : médicaments à usage vétérinaire).
Les résultats de l'inspection/audit confirment que le procédé de fabrication est conforme aux principes et directives de
bonnes pratiques de fabrication susmentionnées.

Et dont les opérations sont déclarées en Annexe I répond aux normes de fabrication.
Ce certificat devient invalide si les activités et / ou opérations certifiées subissent des modifications ou si le site n'est plus
considéré comme conforme aux BPF.
Ce certificat de conformité de BPF est délivré pour servir et valoir qui de droit.
Ce certificat est valable pour une durée de deux ans à compter de sa date de signature

Fait à Libreville le, **02 JUN 2022**
Le Directeur
Dr. Ange MIBINDZOU MOUËLET

GMP

Certificate of Compliance with Good
Manufacturing Practices

Nkôk

Production site in the Special
Economic Zone

Batches


Quality control and finished product release

What this changes

- Gabon can move from raw roots to pharmaceutical processing.
- Foreign partnerships may be contingent on a certain percentage of local value added.
- An iboga supply chain can be aligned with GMP standards, clinical trials, export, traceability, and royalties.
- The government can focus on industry, not just conservation.

Gabon must not become merely the guardian of iboga. It must become the global hub for its ethical processing.

Making Gabon the essential hub: Forest → Industry → Export



Strategic Principle: No international partner should have long-term access to iboga, its derivatives, or the associated knowledge without contributing to the value chain in Gabon.

The world no longer wants just iboga: it wants Gabonese knowledge

Safety

contraindications, screening, cardiac risks

Dosage

protocols, preparation, suitability for treatment

Indications

addiction, trauma, diabetes, fertility, cancer...
to be documented

Culture

botany, domestication, sustainability

Support

assessment, insights, interpretation, complementary
plants

Legitimacy

Bwiti, communities, consent, rituals, and
history

No artificial intelligence, no laboratory, and no fermentation process can recreate centuries of living knowledge if Gabon documents and protects it properly.

The global economy is already here—almost entirely beyond Gabonese control

12,000–15,000

Number of people treated outside Gabon, as estimated in 2012

\$4,500–15,000

Average Costs of Medical Programs in 2026

\$26,600

Identified Premium Offers

400 hours

“Iboga Provider” training programs claimed by private entities

A matter of national honor: How can we accept that foreign private entities certify “iboga therapists” using Bwiti, when Gabon has not yet convened its own National Conference?

Decision: Map, register, monitor, and enter into contractual agreements with all operators using iboga, ibogaine, or Gabonese traditional knowledge—both abroad and in Gabon.

Gabon is not defenseless: it must go on the offensive

Nagoya

Prior Informed Consent, MAT, Benefit-Sharing

WIPO 2024

Disclosure of the Origin of Resources and Knowledge

Gabonese Prior Art

Documenting Knowledge to Block Abusive Patents

Patent Offices

Third-Party Observations, Oppositions, Litigation

Economic Diplomacy

Bilateral Agreements with the United States, Europe, China, and Canada

High-Value Contracts

Licenses, Royalties, Research, Data, Co-Development

The goal is not to hinder global science. The goal is to ensure recognition that any value derived from iboga must pass through Gabon and its communities.

National Iboga Conference: Transforming the Alert into a Framework for State Policy

Day 30

Operational Decree

Implementing Orders, Provisional Registry, Moratorium on Unaccredited Training Programs

Day 45

Rapid Mapping

Licenses, Clinics, Providers, Operators, Inventories, Plantations, Communities

Day 60

National Conference

Government, Communities, Scientists, Legal Experts, Civil Society, International Partners

Day 90

National Plan

National Authority, Funds, Licenses, Litigation, R&D, Plantation Sector, GMP

the iboga sector a sovereign, state-led industry, with communities as co-owners of the value.

Decisions Requested from the Vice President

- 1 Approve the first National Iboga Conference under the high patronage of the State.
- 2 Establish an interministerial task force to address economic, legal, and geostrategic crises.
- 3 Launch, within 30 days, a global mapping initiative covering patents, clinics, training programs, supply chains, and China.
- 4 Commission an international audit of legal remedies: Nagoya Protocol, WIPO, patents, contracts.
- 5 Activate Pharmaceutical Health as a pillar of a Gabonese GMP platform.
- 6 Create a seed fund + sovereign wealth fund + BOTF technical support.
- 7 Declare that any unauthorized use of Gabonese knowledge is subject to challenge.
- 8 Prepare a targeted diplomatic mission: Washington, Geneva/WIPO, Brussels, Beijing.

If Gabon does not take the lead on iboga now, it will have to ask for permission to use its own heritage in the future.

Primary Sources Used



- BOTF / Dr. Joseph P. Barsuglia, Ibogaine Biotechnology – Industry Primer & Report for the Government of Gabon, April 2026.
- Dr. Joseph Barsuglia, Gabon Presentation FINAL copy FRENCH, July 2026.
- Yann Guignon / Traits d'Union, Iboga – Current Status & Outlook in Gabon and Internationally, June 2012.
- Global Iboga Patent Database – March 2026; complete WIPO iboga database.
- Office of the President of the Gabonese Republic, Final Communiqué of the Council of Ministers, April 30, 2026.
- GMP Certificate for La Santé Pharmaceutique SA, Medicines Agency, June 2, 2022.
- BOTF, China, Iboga, and Gabon — Strategic Brief, July 2026.
- Reuters/AP/White House 2026; WIPO Treaty 2024; Nagoya Protocol; public sector-specific pages.

Note: Market figures are strategic estimates intended to inform policy decisions. They must be corroborated by an economic study commissioned by the government.